GlassScriptPhysician profile
Jean M Lenz
NPI 1588044051
$1,171.48
in general payments reported to CMS, 2019-2025
20 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.98 · 2022: $284 · 2023: $154 · 2024: $567 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.76 | 2024 | Farxiga, Breztri |
| Amgen INC. | $165.97 | 2022-2024 | Prolia, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $113.96 | 2022-2025 | |
| Pfizer INC. | $102.90 | 2023-2025 | |
| Novo Nordisk INC | $98.50 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.73 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $60.23 | 2022-2025 | |
| Lilly USA, LLC | $55.83 | 2022-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $53.85 | 2024-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $41.71 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $41.19 | 2024-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $27.12 | 2024 | Nucala |
| Biogen, INC. | $23.65 | 2024 | Skyclarys |
| Medtronic, INC. | $20.84 | 2023 | Minimed 780g |
| Boston Scientific Corporation | $19.96 | 2024 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.46 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.34 | 2024 | |
| Daiichi Sankyo INC. | $16.80 | 2024 | Injectafer |
| Astellas Pharma US INC | $12.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Lenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.